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Original article
Hypertension (HTN) represents a major therapeutic chal-
lenge to healthcare systems worldwide; it affects almost 1 
billion people and is estimated to be the cause of approxi-
mately 7.5 million deaths per year.1–3 The prevalence of 
HTN is expected to increase from 26.4% in 2000 to 29.2% 
in 2025.4 In most countries, many hypertensive individu-
als are not aware of their condition, and among those who 
are aware, many are either not treated or are treated but not 
controlled.5,6 Although various pharmacological and non-
pharmacological treatment options exist, blood pressure 
(BP) control is suboptimal, particularly in low- and middle-
income countries.
In China, high BP is the leading risk factor for cardiovas-
cular disease (CVD).7 Data from 4 large-scale surveys on 
HTN in China showed that the prevalence of HTN is rising 
continuously.8 Currently, it is estimated that there are 153 
million patients with HTN in China, and the rates of aware-
ness, treatment, and control are 25%, 20%, and 4%, respec-
tively.9 The direct medical cost due to HTN is 5.7 billion US 
dollars per year, and the yearly medical cost of CVD that is 
closely related to HTN is as high as 20.6 billion US dollars.7
The reason for poor control of HTN is complex and relates 
to healthcare system characteristics, healthcare providers 
skills, and patients adherence to therapy.10 Primary care phy-
sicians’ attitudes and practice patterns (recognition, treat-
ment, and management) have received increased attention 
as determinants of BP control.11,12 There has been a marked 
increase in the number of prescriptions for antihypertensive 
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background
Blood pressure (BP) control in China is generally poor. It is assumed that 
an important cause of this unsatisfactory situation is the present stand-
ard of care provided by primary care physicians.
methods
One thousand community health centers (CHCs) were selected across 
China based on geographical location, previous cooperative experi-
ence, and acceptance of an invitation to implement a standardized pro-
tocol of community-based BP management. Baseline information for 
each hypertensive patient under the care of these CHCs was collected, 
and the present pattern of hypertensive drug treatment was analyzed.
results
Of all identified hypertensive patients (n  =  249,830), 37% were treated 
with drugs. Characteristics linked with hypertension treatment included 
systolic BP, age, sex, region, smoking and alcohol consumption status, 
body mass index, comorbidities, and family history. The most frequently 
prescribed classes of antihypertensive drugs were diuretics (56.0%), fol-
lowed by centrally active drugs (CADs) (38.3%), calcium channel blockers 
(CCBs) (36.8%), vasodilators (26.5%), and angiotensin-converting enzyme 
inhibitors (ACEIs) (23.3%). In regards to drug combination patterns, diuret-
ics plus CADs was the most frequently used 2-drug combination (61.4%) 
and vasodilators plus CADs plus diuretics was the most frequently used 
3-drug therapy (69.2%). Seventy-seven percent of patients on combina-
tion therapy were prescribed single pill combinations, 87.2% of which 
were composed of CADs and vasodilators and 12.8% of which were com-
posed of ACEIs and diuretics. The control rates of patients on monotherapy 
and combination therapy were 27.7% and 24.1% (P < 0.05), respectively.
conclusions
Our study identified major shortcomings in the present status of anti-
hypertensive pharmacotherapy in routine medical practice in China. It 
is essential to implement a program of professional education regard-
ing the appropriate use of antihypertensive drugs.
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drugs and the use of multiple antihypertensive medica-
tions.13,14 Similar increases in the use of antihypertensive 
drugs have been noted in longitudinal national surveys.15,16
To the best of our knowledge, no data have been published 
on drug use and associated BP control in community-based 
routine practice in China.
In this study, we assessed the present pattern of antihyper-
tensive drug therapy and level of HTN control by analyzing 
relevant information provided to us by cooperating commu-
nity health centers (CHCs) across China.17
METHODS
Project design
The Project of Hypertension Control in CHCs was a 
government-funded program aimed to improve the con-
trol rate of HTN in CHCs across China. For this project, a 
Coordinating Center was established at Fuwai Hospital, 
Beijing. A community-based standardized BP management 
protocol was developed in 2007 based on the 2005 Chinese 
Hypertension League guidelines,7 which were similar to the 
2003 World Health Organization/ International Society of 
Hypertension guidelines18 with respect to classification of 
BP, stratification of global risk, and the principles of treat-
ment. One thousand CHCs were recruited to test the feasibil-
ity of this protocol in a primary care setting and its effect on 
HTN control. CHCs were selected based on the following: (i) 
geographical location, to ensure that various areas of China 
would be covered; (ii) previous cooperation with our group 
at the Fuwai Hospital; and (iii) acceptance of the invitation 
to participate in the present project. Primary care physicians 
from these CHCs were trained by the Coordinating Center.
Patients
Patients with diagnosed HTN who were aged 18–79 years 
were recruited by the physicians in the cooperating CHCs to 
participate in this project. The following exclusion criteria 
were applied: (i) diagnosis of secondary HTN; (ii) diagnosis 
of acute coronary syndrome and/or stroke (<3 months after 
onset); (iii) mental disease, hearing difficulty, physical inca-
pacitation, or uncooperative behavior; and (iv) life expec-
tancy of <1 year.
Written informed consent for the baseline survey was 
required from each participant. Institutional ethics review 
board approval was obtained at the Coordinating Center, and 
the study was conducted in accordance with the ethical prin-
ciples of the Declaration of Helsinki and the International 
Conference on Harmonization of Good Clinical Practice.
Data collection
Data on demographics, cardiovascular risk profile, comor-
bidities, BP, and antihypertensive drug usage were collected 
using a case report form designed by the Coordinating 
Center (see Supplementary Appendix 1).
In this study, the prescription information on antihyper-
tensive drugs was analyzed for each patient. Medications 
were classified as diuretic (DIU), beta-blocker (BB), alpha- 
blocker, calcium channel blocker (CCB), angiotensin-con-
verting enzyme inhibitor (ACEI), AT1 receptor blocker 
(ARB), centrally acting drugs (CADs, such as reserpine, clo-
nidine), vasodilators (VASOs, such as dihydralazine, diba-
zole, pargyline), and Chinese traditional medicine (CTM). 
Single-pill combinations (SPCs), which normally contain 
≥2 active ingredients (see Supplementary Appendix 2), were 
separated into their generic components. Each medication 
was classified into only 1 category. Respondents who used 
only 1 drug were defined as receiving monotherapy; those 
using ≥2 drugs were defined as combination therapy.
BP was measured on the right arm in a seated position 
and after 5 minutes of rest in all participants during the 
clinic visit using a mercury sphygmomanometer. The mean 
of 2 measurements was used for analysis. HTN was defined 
as systolic BP ≥140 mm Hg, and/or diastolic BP ≥90 mm Hg, 
and/or use of antihypertensive drug. Respondents smok-
ing at least 1 cigarette per day were classified as smokers. 
Drinking was defined as having alcoholic beverages at least 
once a week. Self-reported diabetes, coronary heart disease, 
stroke, and renal disease were recorded as associated clinical 
conditions (ACCs). Family history of CVD, such as HTN, 
diabetes, coronary heart disease, and stroke among first-
degree relatives, was also noted.
Statistical analysis
Data from each local center were recorded in uniform 
record forms and submitted to the Coordinating Center 
by trained staff using an online data entry system. The data 
were analyzed centrally at the Fuwai Hospital in Beijing. All 
statistical analyses were performed with SPSS software ver-
sion 15.0 (SPSS, Chicago, IL). Continuous variables were 
expressed as means (SD), and categorical variables were 
expressed as counts (percentages). Z tests were used for con-
tinuous data, and χ2 tests were used to compare the categori-
cal variables. All statistical tests were 2-tailed, and P < 0.05 
was considered statistically significant.
RESULTS
From March 2007 to December 2010, a total of 255,168 
hypertensive patients were enrolled from 8 provinces in 
China: Hebei, Guangdong, Zhejiang, Gansu, Jiangsu, Beijing, 
Qinghai, and Shandong. From this sample, 249,830 patients 
were eligible for analysis, of which 48.3% of respondents were 
men and their mean age was 61.0 ± 10.5 years. With respect 
to treatment, 92,325 (37%) respondents from the study sam-
ple were treated with antihypertensive drugs (Table 1). Age, 
systolic BP, and urban residence, as well as proportions of 
smoking, drinking, obesity, ACC, and family history, were 
higher among treated patients with HTN (P < 0.05).
Overall, 27% of patients with HTN had their BP con-
trolled (Table 2). The control rate of BP was higher among 
patients who were elderly, female, or living in urban area 
(P < 0.05). On the other hand, smoking, drinking, and higher 
body mass index were associated with lower BP control rate, 
whereas patients with positive family history and ACCs had 
a higher BP control rate.
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Overall, DIUs were the most frequently prescribed drugs, 
followed by CADs, CCBs, and VASOs. The proportions of 
prescriptions were 24.5% for ACEIs, 4.1% for ARBs, 10.4% 
for BBs, and 0.1% for alpha-blockers (Figure 1).
For patients on monotherapy, CCBs had the high-
est prescription rate, followed by ACEIs, DIUs, and BBs; 
no alpha blockers, CADs, or VASOs were prescribed 
(Figure  1). With respect to combination therapy, the 
most commonly prescribed 2-drug combination was 
DIUs+CADs; 2.6% of patients used ACEIs+BBs combina-
tion. VASOs+CADs+DIUs was the most frequent 3-drug 
combination. About 77% of patients on combination ther-
apy were prescribed SPCs. As to the content of SPCs, 87.2% 
were composed of CADs, VASOs, and DIUs; 12.8% were 
composed of ACEIs and DIUs; and <1% were composed of 
others (Figure 2).
Overall, 36.5% of patients were on monotherapy, and 
63.5% were on combination therapy, with corresponding 
HTN control rates of 27.7% and 24.1%, respectively (P < 0.05) 
(Table 3). Patients with controlled HTN were more often on 
monotherapy than on combination therapy (P < 0.05). The 
control rate was higher in women, the elderly, those living in 
urban areas, and those with self-reported ACCs (P < 0.05), 
whereas it was lower among those who smoked, consumed 
alcohol, had a body mass index ≥28 kg/m2, and reported a 
positive family history.
DIScUSSION
Knowledge about the characteristics associated with 
hypertensive treatment and the present prescription pat-
tern of antihypertensive drugs by primary care physicians 
helps to identify shortcomings in the treatment of hyper-
tensive patients and facilitate the development of plans for 
improvement.
In this study, almost all patients recruited from CHCs 
were aware of their condition and had higher rates of treat-
ment (37.3%) and control (27%) than those identified in 
a cross-sectional survey of the general population in 2002 
(20% and 4%, respectively).9 However, the control rate was 
lower than that from the survey on outpatients in tertiary 
hospitals in 2009 (30.6%).19 This is expected because doc-
tors in tertiary hospitals have more knowledge and experi-
ence in antihypertensive treatment and patients treated in 
these hospitals can usually afford the cost of diagnosis and 
treatment.
Table 1. Characteristics of untreated and treated patients with hypertension in community health centers in China
Variables Untreated (n = 157,505) Treated (n = 92,325) Total (n = 249,830)
Sex, malea 77,809 (49.4) 42,899 (46.5) 120,708 (48.3)
Age, y, mean (±SD)* 60.7 (10.6) 61.5 (10.3) 61.0 (10.5)
Age group, y*
 18–44 5,562 (3.5) 2,423 (2.6) 7,985 (3.2)
 45–64 64,992 (41.3) 36,903 (40.0) 101,895 (40.8)
 >64 86,951 (55.2) 52,999 (57.4) 139,950 (56.0)
SBP, mm Hg, mean (±SD)* 143 (16) 145 (17) 144 (17)
DBP, mm Hg, mean (±SD) 88 (10) 88 (11) 88 (10)
BP level, mm Hg*
 <140/90 43,987 (28.0) 23,470 (25.5) 67,457 (27.0)
 141–159/91–99 73,587 (46.8) 41,714 (45.3) 115,301 (46.2)
 160–179/100–109 30,711 (19.5) 19,932 (21.6) 50,643 (20.3)
 ≥180/110 9,023 (5.7) 7,066 (7.7) 16,089 (6.4)
Region*
 Rural area 109,931 (69.8) 54,556 (59.1) 164,487 (65.8)
 Urban area 47,574 (30.2) 37,769 (40.9) 85,343 (34.2)
Smoking* 26,807 (17.0) 17,096 (18.5) 43,903 (17.6)
Drinking* 22,354 (14.2) 15,039 (16.3) 37,393 (15.0)
Obesity* 21,399 (13.6) 14,580 (15.8) 35,979 (14.4)
ACC* 20,258 (12.9) 17,460 (18.9) 37,718 (15.1)
Family history* 30,935 (19.6) 25,182 (27.3) 56,117 (22.5)
Data are presented as No. (%) unless otherwise indicated. Variations in numbers are because of missing data. Obesity was defined as a body 
mass index ≥28 kg/m2, and family history was positive if cardiovascular disease history, such as hypertension, diabetes, coronary heart disease, 
and stroke among first-degree relatives, was reported.
Abbreviations: ACC, associated clinical condition, including self-reported diabetes, coronary heart disease, stroke, and renal disease; BP, 
blood pressure; DBP, diastolic blood pressure; SBP, systolic blood pressure.
*Difference between untreated and treated groups significant at P < 0.05.
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Patients’ characteristics associated with untreated HTN 
included male sex, young age, low systolic BP, living in a 
rural area, being a nonsmoker and nondrinker, having a 
lower body mass index, absence of comorbidities, and nega-
tive family history. These characteristics were consistent 
with other studies.20,21
Interestingly, the BP control rate among treated patients 
with HTN was found to be lower than that of untreated 
hypertensive patients. Further analysis showed that treated 
patients were more likely to be current smokers and drink-
ers, had a higher body mass index, indicated the presence of 
ACCs, and reported a positive family history. Among these 
types of patients, it is usually difficult to reach the BP control 
goal. Another possible explanation for this observation may 
be that the problem lies with poor adherence to prescribed 
therapy. With respect to untreated hypertensive patients 
with controlled BP, it is possible that they may have taken 
drugs or undertaken lifestyle changes in the past but were 
not taking any antihypertensive medication at the time of 
the survey. It would also be important to note that it is now 
a common phenomenon in China for hypertensive patients 
to discontinue taking their antihypertensive drugs when 
Table 2. Control rate for untreated and treated patients with hypertension by characteristics
Subgroup
Untreateda Treated Total
No. % No. % No. %
Total 43,987 27.9* 23,470 25.4 67,457 27.0
Sex
 Male 20,010 25.7* 9,920 23.1 29,930 24.8
 Female 23,977 30.1* 13,543 27.4 37,520 29.1
Age group, y
 18–44 990 17.8* 374 15.4 1,364 17.1
 45–64 16,461 25.3* 8,538 23.1 24,999 24.5
 >64 26,536 30.5* 14,558 27.5 41,094 29.4
Region
 Rural area 27,720 25.2* 11,430 21.0 39,150 23.8
 Urban area 16,267 34.2 12,040 31.9 28,307 33.2
Smoking
 Nonsmoker 37,401 28.6 20,063 26.7 57,464 27.9
 Smoker 6,586 24.6 3,404 19.9 9,990 22.8
Drinking
 Nondrinker 38,675 28.6* 20,521 26.6 59,196 27.9
 Drinker 5,312 23.8* 2,946 19.6 8,258 22.1
BMI, kg/m2
 < 28 39,254 28.8* 20,676 26.6 59,930 28.0
 ≥ 28 4,733 22.1* 2,794 19.2 7,527 20.9
ACC
 No 37,895 27.6* 18,803 25.1 56,698 26.7
 Yes 6,092 30.1* 4,667 26.7 10,759 28.5
Family history
 No 34,119 27.0* 17,442 26.0 51,561 26.6
 Yes 9,868 31.9* 6,028 23.9 15,896 28.3
Data are presented as number and percentage of hypertensive patients with controlled blood pressure.
Abbreviations: ACC, associated clinical condition, including self-reported diabetes, coronary heart disease, stroke, and renal disease; BMI, 
body mass index.
aDuring our survey, a large number of patients previously diagnosed with hypertension had a normal blood pressure (BP); however, they were 
not using antihypertensive medication at the time of the survey. The possible explanations for this are as follows: (i) patients could have been 
incorrectly labelled as hypertensive based on 1 or 2 casual measurements of elevated BP, however, their BP reading at the time of the survey 
was in the normal range; (ii) similarly, some individuals could have had elevated BP initially but spontaneously reversed to normal BP values 
(i.e., regression towards the mean); (iii) an unknown number of patients could have been on antihypertensive medication but discontinued use 
before inclusion in the survey, which resulted in them falling in the untreated subgroup with non-elevated BP; and (iv) finally, patients could have 
been treated with nonpharmacological methods.
*P < 0.05 for the difference between untreated and treated groups.
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BP control is achieved, resulting in a false control status for 
untreated patients. Finally, perhaps untreated hypertensives 
had transiently elevated BP at an earlier occasion, which may 
have spontaneously returned to normal at the time of our 
survey, resulting in the detection of BP levels <140/90 mm 
Hg in the absence of antihypertensive drug therapy.
The 2005 Chinese Hypertension League guidelines,7 as well 
as the 2003 World Health Organization/ International Society 
of Hypertension guidelines,18 recommend that all classes of 
antihypertensive drugs can be used for initiation and main-
tenance of treatment in all hypertensive patients. Our data 
showed that DIUs were most frequently used (56.0%), followed 
by CADs (38.3%), CCBs (36.8%), VASOs (26.5%) and ACEIs 
(24.5%). For patients on monotherapy, CCBs were the pre-
ferred drugs (54.3%), followed by ACEIs (23.3%), DIUs (8.9%), 
and BBs (7.7%). An alpha-blocker was seldom prescribed. The 
major cause of this significant difference was that most SPCs, 
which mostly consist of CADs, VASOs, and DIUs, were pre-
scribed for patients on ≥2 therapies but not on monotherapy.
On the basis of clinical trial results, ARBs/ACEIs are rec-
ommended for several compelling indications, such as dia-
betes, nephropathy, coronary and cerebrovascular disease, 
heart failure, and left ventricular hypertrophy.7,18 In this 
sample, the prescription rate of ARBs was not >5.0%, much 
lower than that in tertiary hospitals in China (32.0%)19 and, 
for example, in Canada (71%).22 Newer drugs were seldom 
used, despite the recommendation in the guidelines.7
HTN guidelines suggest the use of a single drug initially, 
which may be followed by adding more medications according 
to the patients’ response to the drug to achieve the goal BP. Based 
on our observations, about 63.5% of patients were on combi-
nation therapy, with DIUs+CADs as the highest prescribed 
2-drug combination (61.4%), and VASOs+CADs+DIUs as the 
highest prescribed combination of 3 drugs (69.2%). SPCs, as 
a fixed combination tablet, have advantages in terms of com-
pliance and BP-lowering efficacy and are recommended as a 
substitute for free combination of drugs.23 In this study, nearly 
90% of SPCs were conventional fixed-dose combination drugs, 
which were mostly produced by domestic companies in China. 
New fixed-dose combination drugs were rarely prescribed (e.g., 
12.8% for ACEIs/hydrochlorothiazide, 0.1% for ARBs/ hydro-
chlorothiazide). Remarkably, the treatment of HTN showed 
great adherence to conventional pharmacotherapy, whereas 
newer drugs were being added at a slow pace. The reasons for 
frequent use of traditional SPCs could be as follows: (i) deeply 
entrenched traditional prescription habits of the primary care 
physicians; (ii) physicians’ lack of knowledge or willingness to 
adhere to the new guidelines for the treatment of HTN; (iii) 
easy availability; and (iv) affordable pricing for most traditional 
SPCs compared with new SPCs.
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Figure 1. Proportion of antihypertensive drugs provided as both monotherapy and combination therapy or as monotherapy in community health centers 
in China. In the drugs provided as both mono- and combination therapy group, ingredients of the single-pill combinations were separated and pooled with 
the classes of drugs that were used as monotherapy. Abbreviations: AB, alpha-blocker; ACEI, angiotensin-converting enzyme inhibitor; ARB, AT1 receptor 
blocker; BB, beta-blocker; CAD, centrally acting drug; CCB, calcium channel blocker; CTM, Chinese traditional medicine; DIU, diuretic; VASO, direct vasodilator.
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Figure  2. Proportion of active ingredients in single-pill combinations 
widely used for the treatment of hypertension in community health cent-
ers in China. Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; 
ARB, AT1 receptor blocker; CAD, centrally acting drug, such as reserpine and 
clonidine; CTM, Chinese traditional medicine; HCTZ, hydrochlorothiazide; 
VASO, direct vasodilator; such as dihydralazine, dibazole, and pargyline.
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As to the urban/rural difference, patients in rural areas 
are usually poorer than those in urban areas, and only a few 
have medical insurance. Lack of insurance is a factor limit-
ing healthcare use.24
The control rate among treated HTN was only 25.4%, 
somewhat lower than the 29.4% in primary care in Germany25 
and the 30.6% in tertiary hospital clinics in China.19 The 
control rate was higher on monotherapy (27.7%) than 
combination therapy (24.1%), similar to a study in Canada 
(86% and 80%, respectively),22 but in contrast with Joshi 
et al.’s study (40.8% and 59.2%, respectively).26 Because the 
data are derived from a cross-sectional baseline survey, it is 
unclear whether the present therapy was the initial one or 
whether it replaced or amended the original one. A possible 
reason for the low rate of HTN control on combination ther-
apy may be that, in this sample, there was a larger proportion 
Table 3. Percentage of patients with hypertension by characteristics on monotherapy vs. combination therapy and associated control rates
Subgroup
Monotherapy Combination therapy Total
% % Controlled % % Controlled % % Controlled
Total 36.5 27.7** 63.5 24.1 100.0 25.4
Sex
 Male 47.3* 25.4** 46.0 21.8 46.5 23.1
 Female 52.7 29.7** 54.0 26.1 53.5 27.4
Age group, y
 18–44 3.0* 17.1 2.4 14.3 2.6 15.4
 45–64 38.6 26.1** 40.8 21.5 40.0 23.1
 >64 58.4 29.3** 56.8 26.4 57.4 27.5
BP level, mm Hg
 < 140/90 27.7* 100.0 24.2 100.0 25.5 100.0
 141–159/91–99 44.6 — 45.7 — 45.3 —
  160–179/100–109 20.9 — 22.0 — 21.6 —
 ≥ 180/110 6.8 — 8.2 — 7.7 —
Region
 Rural area 47.7* 18.4** 65.6 22.0 59.1 21.0
 Urban area 52.3 36.1 34.4 28.2 40.9 31.9
Smoking
 Nonsmoker 82.8* 28.9** 80.7 25.4 81.5 26.7
 Smoker 17.2 21.8** 19.3 19.0 18.5 19.9
Drinking
 Nondrinker 84.6* 28.8** 83.2 25.3 83.7 26.6
 Drinker 15.4 21.7** 16.8 18.5 16.3 19.6
BMI, kg/m2
 <28 85.4* 28.6** 83.5 25.4 84.2 26.6
 ≥28 14.6 21.9** 16.5 17.8 15.8 19.2
ACC
 No 78.9* 27.0** 82.4 24.1 81.1 25.1
 Yes 21.1 30.2** 17.6 24.4 18.9 26.7
Family history
 No 74.1* 27.8** 71.9 24.9 72.7 26.0
 Yes 25.9 27.2** 28.1 22.2 27.3 23.9
Data are presented as percentage of hypertensive patients on monotherapy or combination therapy and proportion with controlled 
hypertension.
Abbreviations: ACC, associated clinical condition, including self-reported diabetes, coronary heart disease, stroke, and renal disease; BMI, 
body mass index; BP, blood pressure.
*P  <  0.05 for the difference in proportion of hypertensives between monotherapy and combination therapy groups; **P  <  0.05 for the 
 difference in control rate between monotherapy and combination therapy groups.
American Journal of Hypertension 7
Prescription Patterns in Community Health Centers in China
of patients with cardiovascular disease risk factors and other 
clinical conditions requiring intensive treatment. The diffi-
culty of reducing BP level to the recommended target level 
in these patients is well known.27–29 One logical option, how-
ever, for improving BP control in these patients is to include 
an additional antihypertensive medication. Unfortunately, 
as described above, the current combinations of medicines 
were not only inconsistent with what the guidelines recom-
mend but also included some old agents, thus creating a bar-
rier to better HTN control.
One of the study limitations was that the data were 
retrieved from a nonrandom sampling program. Second, 
we did not collect information about physicians’ knowledge 
of antihypertensive drug use. Third, adherence to medica-
tion was not assessed, and medication dose and frequency 
were not recorded. Finally, although lifestyle change is also 
important for BP control, our analysis focused on drug 
treatment.
The strength of this project was the large sample size and 
the cooperation of a large number of CHCs in collecting 
unique data about the treatment of hypertensive patients by 
primary care physicians in China.
The finding of low control rates among treated patients in 
China can be explained by the present pattern of antihyper-
tensive drug therapy in routine practice (i.e., high prescrip-
tion rates of traditional SPC and suboptimal combinations 
of contemporary, efficacious drugs).
Our data will be helpful in designing and implement-
ing a program of professional education on the use of 
appropriate antihypertensive medications alone or in the 
correct combinations and ensuring that patients receive 
evidence-based, cost-effective treatments for their health 
problems.
SUPPLEMENTARY MATERIALS
Supplementary materials are available at American Journal 
of Hypertension (http://ajh.oxfordjournals.org).
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Appendix 1 1 
Baseline Form                                    2 
ID:  (Center) -  (Patient)         Filling Date: // (yyyy/mm/dd)  3 
1. Patient Name:             
2. Birth Date: //(yyyy/mm/dd) 
3. History of Cardiovascular Diseases: 
3.1 Hypertension:    0=No  1=Yes ( Course:       years)   9=Unknown 
3.2 Diabetes:        0=No  1=Yes ( Course:       years)   9=Unknown 
3.3 Angina pectoris:  0=No  1=Yes ( Course:       years)   9=Unknown 
3.4 Myocardial infarction:  0=No  1=Yes ( Course:       years)   9=Unknown 
3.5 Stroke:  0=No  1=Yes ( Course:       years)   9=Unknown 
3.6 Transient ischemic attack:  0=No  1=Yes ( Course:       years)   9=Unknown 
3.7 Other (periferal vascular disease, kidney disease): 0=No  1=Yes ( Course:       years)   9=Unknown 
4. Family History of Cardiovascular Diseases 
4.1 Hypertension:  0=No  1=Yes   9=Unknown 
4.3 Coronory heart disease:  0=No  1=Yes  9=Unknown 
 
 
4.2 Diabetes :  0=No  1=Yes   9=Unknown 
4.4 Stroke:    0=No  1=Yes   9=Unknown 
5. Physical Examination  
5.1 Height cm     5.2 Weight .kg      5.3 BP ／mmHg (mean of 3 readings) 
6. Laboratory Test  
6.1 Glucose:  .mmol/L  or mg/dL 
6.2 Total Cholesterol:  .mmol/L  or mg/dL 
6.3 Triglyceride:  .mmol/L  or mg/dL 
6.4 High density lipoprotein cholesterol: .mmol/L  or mg/dL 
6.5 Serum creatinine: .μmol/L  or .mg/dL  
6.6 Urine protein:  0 = negative,  1 = +,  2 = ++,  3 = +++ 
6.7 Left ventricle hypretrophy (using ECG):  0=No  1=Yes   9=untested 
7. Life Style 
7.1 In recent month, the mean alcohol consumption per day:  1=no  2=Yes (       mill liter/day) 
7.2 Inrecent month, the mean cigarettes per day:  1=no  2=Yes (       cigarettes/day) 
7.3 How amny times do you do exercise in a week?   1=no  2=Yes (       times/week) 
7.3.1 How long dose it last:        min/time 
8. Drug Usage 
8.1 Have you taken any anti-hypertensive drug in recent two weeks?   0=No   1=Yes 
   8.1.1 If YES, what is the name of drugs which you are using now (Approved Drug Names)? 
        No.1:                         No.2:                     
No.3:                         No.4:                     
No.5:                         No.6:                     
Doctor Signature: __________________ 4 
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Appendix 2 5 
Single-pill combination (SPC) is a pill combining a variety of antihypertensive, mostly 6 
less-used, drugs. The SPC use has a long tradition in Chinese primary care practice. 7 
There are various types of SPC on the market under different trade names. Further 8 
details are listed in the table below. The SPC is popular among physicians because of 9 
previous experience, and among patients due to their low cost. 10 
Single Pill Combination Component 
Traditional SPC  
Compound Hypoensive Tablets Hydrochlorothiazide, Triamterene,  
Dihydralazine, Reserpine 
Compound Reserpine Tablets Reserpine, Hydrochlorothiazide, Vitamin B6, 
Mixed spin calcium pantothenate, Magnesium 
trisilicate, Potassium chloride, Vitamin B1, 
Dihydralazine, Promethazine 
Compound reserpine and 
 hydrochlorthiazide tablet 
Reserpine, Hydrochlorothiazide, Rotundine, 
Potassium chloride 
Compoud Pargyline Tablets Pargyline, Reserpine, Dihydralazine, 
 Diazepam, Promethazine, Dibazole, Rutin, 
Vitamin B 
Compound Bendazol and 
Hydrochlorothiazide Capsules 
Dibazole, Promethazine, Chloroquine 
phosphate, Guanoxan sulfate, Vitamin B6, 
Potassium chloride, Reserpine, 
Chlordiazepoxide, Hydrochlorothiazide, 
Calcium lactate, Vitamin B1, Magnesium 
trisilicate 
Compound Dihydralazine Tablets Dihydralazine, Hydrochlorothiazide, Reserpine, 
Enduronyl Methyclothiazide, Deserpidine 
Zhenjujiangyapian Clonidine, Hydrochlorothiazide, Flos 
Chrysanthemi Indici, Flos sophorae, Nacre 
powder 
Compound Kendir Leaves Tablets Kendir, Flos Chrysanthemi Indici, Tsuzura, 
Magnesium trisilicate, Dihydralazine, 
Hydrochlorothiazide,  Promethazine, Vitamin 
B1, Vitamin B6, Calcium lactate 
Fufanglingjiaojiangyapian Antelope Horn , Prunella vulgari, Scutellaria, 
Mistletoe 
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Duzhongjiangyapian Eucommia ulmoides, Leonurus japonicas, 
Prunella vulgari, Scutellaria, Uncaria 
Normal SPC  
ARB +DIU Irbesartan, Hydrochlorothiazide 
 Losartan, Hydrochlorothiazide 
ACEI +DIU Captopril, Hydrochlorothiazide 
Amiloride+DIU Amiloride, Hydrochlorothiazide 
Abbreviations: ACEI, angiotensin converting enzyme inhibitor; ARB, AT1 receptor 
blocker; DIU, diuretic; SPC, single pill combination. 
 11 
